Fig. 3

Risk stratification of AML according to gene mutations and gene expression level. Low risk: biallelic CEBPA mutation; Intermediate risk I: low MECOM and MEIS1 without biallelic CEBPA mutation or NPM1-mut/DNMT3A-wt; Intermediate risk II: others; High risk: FLT3-ITD/TKD with the absence of NPM1-mut/DNMT3A-wt or DNMT3A mutation or high MECOM and MEIS1. a OS, b DFS